Inflammation or inflammatory cytokines and oxidative stress have often been associated, and thiol antioxidants, particularly glutathione, have often been seen as possible anti-inflammatory mediators. However, whereas several cytokine inhibitors have been approved for drug use in chronic inflammatory diseases, this has not happened with antioxidant molecules. We outline the complexity of the role of protein thiol-disulfide oxidoreduction in the regulation of immunity and inflammation, the underlying molecular mechanisms (such as protein glutathionylation) and the key enzyme players such as Trx (thioredoxin) or Grx (glutaredoxin).
Introduction

Antioxidants as inhibitors of inflammatory cytokines
Inflammatory cytokines and oxidative stress are often associated in the literature and have many similarities. Both terms began being used in the early 1980s (see http://ngrams.googlelabs.com). Both inflammatory cytokines, particularly IL (interleukin)-1 and TNF (tumour necrosis factor), and oxidative stress have been implicated in so many diseases that it would be difficult to find one where neither has been involved. Both are interpreted with an 'axis-of-evil' perspective, where they play a pathogenic role, and this oversimplification has probably contributed to the rapid diffusion of these two areas or research. However, while in the field of inflammatory cytokines a number of cytokine inhibitors have been developed and approved for therapeutic use (e.g. anti-TNF and anti-IL-6 molecules in rheumatoid arthritis and inflammatory colitis), inhibitors of oxidative stress (antioxidants) are confined to the nebulous area of alternative medicine and none have made the jump to regulatory approval, despite many clinical trials and a large number of molecules tested, a fact that cannot be explained by a conspiracy theory.
Inflammatory cytokines and oxidative stress have more in common than historical similarities. Increased production of inflammatory cytokines and oxidative stress, either defined as an increased production of ROS (reactive oxygen species) or a decrease in the GSH/GSSG ratio, are often associated in many inflammatory diseases. A molecular mechanism for this association was first provided in 1991 with the finding that H 2 O 2 activates the transcription factor NF-κB (nuclear factor κB) which has many inflammatory cytokines among its target genes, while thiol antioxidants inhibit its activation [1] .
Several studies have reported the inhibition of cytokine production by many thiol antioxidants, including GSH or NAC (N-acetylcysteine). Other studies have shown that antioxidants protect from TNF cytotoxicity [2] .
In general, there is a wide acceptance of the equation oxidative stress = inflammation, and GSH is often regarded as an endogenous anti-inflammatory mediator. This actually goes back to the pre-cytokine era, and adds to earlier knowledge of the role of PMN (polymorphonuclear neutrophil)-generated ROS in tissue damage and inflammation [3, 4] , and particularly in sepsis-associated ARDS (acute respiratory distress syndrome), which is characterized by pulmonary inflammation [5] . Interestingly, superoxide dismutase, soon after its identification as an antioxidant enzyme, was investigated as a possible anti-inflammatory drug [6] .
Antioxidants and inflammatory cytokines: a more complex picture
However, biological systems are complex and oversimplifications seldom help. The discovery of the pro-inflammatory role of TNF [7] led to the development of anti-TNF antibodies, a breakthrough in the therapy of chronic inflammatory diseases. However, a few years after U.S. approval, in 1998, of anti-TNF antibodies for the therapy of rheumatoid arthritis, it became clear that TNF blockade caused increased susceptibility to infections, which in some cases was lethal [8] . This reminded researchers that TNF is a Th1 cytokine and therefore an important molecule in innate immunity. Interestingly, usage of the term 'innate immunity' took off almost 10 years after that of the term 'cytokines', but we are now all familiar with the concept of the dual role of innate immunity in host defence compared with tissue damage, which translates in the concept of risk/benefit ratio when using cytokine inhibitors.
The evolution towards a more complex concept, as opposed to a one-way view, is indicated by the recent diffusion of the concept of redox regulation.
Specifically in the field of innate immunity, an obvious question would be: if antioxidants and ROS scavengers are inhibitors of inflammation, should we expect them to inhibit some of the mechanisms of innate immunity, thus worsening infections? The question is not as unrealistic as it seems, as ROS are one of the main antibacterial weapons of PMN [9] , and lack of ROS production by PMN is on the basis of chronic granulomatous disease, characterized by increased susceptibility to infection [10] .
We have attempted to address this question using a model of polymicrobial peritoneal sepsis induced by CLP (caecal ligation and puncture) using as tools a GSH-depleting agent, the GSH synthesis inhibitor BSO (buthionine-SRsulfoximine) and the GSH precursor NAC. We expected that GSH would act as an anti-inflammatory mediator of sepsis-induced ARDS, evaluated as PMN infiltration. In fact, we observed that, in agreement with previous studies, GSH depletion increased pulmonary PMN infiltrate, while NAC decreased it. However, surprisingly, when we looked at PMN migration at the site of infection, inflammatory infiltrate was increased by NAC and decreased by GSH depletion. Possibly as a result of these opposite effects on the inflammatory infiltrate at the site of infection (the peritoneal cavity) and in a distant organ (the lung), survival curves indicated that GSH improved survival [11] .
We concluded that GSH does not simply inhibit inflammation, but rather acts as a regulatory mediator [12] . The molecular basis for the regulatory action of glutathione must be more complicated than simply acting as an antioxidant defence by scavenging ROS.
Molecular basis for the regulatory function of glutathione: the concept of redox-sensitive proteins
Glutathione is not just an antioxidant (in its GSH form). The GSH/GSSG couple also acts as a redox buffer, regulating the redox state of 'redox-sensitive proteins'. In fact, it has long been thought that cysteine residues in proteins can exist in two different forms: free (with the free thiol) or engaged in a disulfide bond, and this is the information that we can obtain if we look up a protein sequence in various databases (http://www.ncbi.nlm.nih.gov/protein; http://www.uniprot.org/). It is also thought that, in general, cytosolic proteins have their cysteine residues mostly in the free thiol ( − SH) state, while secreted proteins have them oxidized as disulfides [13, 14] . This is because the extracellular environment is an oxidizing one, while the cytosol is a reducing one, owing to the high concentrations of GSH and the high GSH/GSSG ratio. The overall concept of redox regulation is based on the fact that many cysteine residues that, in theory (according to the databases), are in the reduced state can in fact exist in various oxidation states. These include: (i) inter-chain disulfides; (ii) mixed disulfides with small molecular mass thiols (e.g. GSH, glutathionylation or with cysteine, cysteinylation); (iii) S-nitrosylation; (iv) oxidation to sulfinic, sulfenic or sulfonic acids (Table 1 ). All these oxidations are reversible (with the possible exception of sulfonic acids), and this reversibility makes these modifications likely mechanisms of regulation of protein function, similar to other posttranslational modifications such as phosphorylation.
Whether a given cysteine residue in a protein is susceptible to these modifications is determined by various factors, including its reactivity (which depends on the neighbouring amino acids) and its accessibility (for instance, reaction with GSH or GSSG to form a glutathionylated protein will have a different accessibility requirement than reaction with H 2 O 2 to form a sulfinic acid [15] ). This is different from protein phosphorylation, which is, in large part, sequence-specific.
Protein thiol-disulfide oxidoreductases: key players in redox regulation
In analogy with protein phosphorylation, which is regulated by protein kinases and phosphatases, cysteine residues can be oxidoreduced by a number of enzymes in the protein thioldisulfide oxidoreductase family (Table 2 ). These include: Trx (thioredoxin), Grx (glutaredoxin) and PDI (protein disulfideisomerase). Prx (peroxiredoxin) can detoxify peroxides by oxidizing Trx. These enzymes, particularly Trx, can catalyse several reactions with many substrates in general, but the reader should bear in mind that this is an oversimplification. Trx, Grx and Prx are considered antioxidant enzymes (which maintain proteins in the reduced state), while PDI is often considered an oxidant, important for the formation of structural disulfides in protein folding. Trx, Grx and PDI all have a CXXC-motif active site (CGPC in Trx, CPYC in Grx, CGHC in PDI) where the two cysteine residues form a transient disulfide as a reaction intermediate. Grx and Trx in particular can reduce glutathionylated proteins at the expense of another reducing agent (GSH) catalysing the thiol-disulfide exchange reaction from right to left:
Other relevant enzymes in this context are Srx (sulfiredoxin) that reduces sulfinic acids to free thiols, and SOXs (thiol oxidases; also with a CXXC motif), which catalyse the formation of protein disulfides.
Protein S-thiolation in regulation of immunity
Since our first study in human T-lymphocytes [16] , many applied proteomic techniques ('redox proteomics') have been used to identify proteins undergoing glutathionylation, and hundreds have been identified to date. Table 3 lists some of those relevant to immunity.
From what is discussed above, it is clear that GSH is not only a free radical scavenger, but also a signalling molecule. Glutathionylation can be either anti-inflammatory or pro-inflammatory depending on the protein targeted. One example of this is provided by the effect of glutathionylation of various proteins in the NF-κB pathway. Glutathionylation of p65-NF-κB leads to its inactivation [26] and glutathionylation of p50-NF-κB inhibits DNA binding [25] , and thus oxidation (glutathionylation) should be anti-inflammatory. On the other hand, glutathionylation inhibits the IKKβ (inhibitor of NF-κB kinase β), which will result in a pro-inflammatory effect of its oxidation [21] . To confirm the contrasting role of glutathionylation, endogenous Grx can both decrease [32] or augment [21, 33] production of inflammatory cytokines, depending on the experimental model.
Protein thiol-disulfide oxidoreductases in immunity
While the main role of protein thiol-disulfide oxidoreductases is intracellularly as redox enzymes, they can also be secreted and have extracellular functions. The enzyme in this family that is most known to immunologists is probably Trx. As early as 1985, Yodoi and co-workers identified a new cytokine that they called ADF (ATL-derived factor), which augmented the expression of the IL-2 receptor [34] and was identical with a factor thought to be an isoform of IL-1 [35] . These were finally identified as Trx [36] . Subsequently various activities of Trx on leucocytes were reported. These include activation of eosinophil cytotoxicity [37] and migration [38] , chemotactic activity towards monocytes, neutrophils and lymphocytes [39, 40] and co-stimulation of TNF production in monocytes [41] . Trx can also be secreted as a C-terminally truncated form (Trx80), which induces IL-12 production and CD14 expression in monocytes [42] . It should be mentioned, however, that some of the immunological actions of Trx are independent of the redox action, as they are also present in redox-dead mutants lacking the CXXC motif [42] . Administration of Trx inhibits leucocyte migration in vivo [43, 44] , possibly by a mechanism of desensitization related to its chemotactic action [40] , and is elevated in several infective or inflammatory pathological conditions (see [45] for a review). The mechanism underlying the extracellular actions of Trx, and possibly other redox-active cytokines, are not yet understood, as no specific receptors have been identified to date. One of the earliest discovered cytokines, macrophage MIF (migration-inhibitory factor) has a CXXC Trx-like domain that is essential for its activity [46] . When secreted, MIF can be cysteinylated, acquiring novel immunological functions, and is identical with a factor once known as GIF (glycosylationinhibiting factor) [23, 24] . Trx is also a component of the elusive immunosuppressive molecule termed 'early pregnancy factor' [47] . Finally, S100 calgranulins can undergo glutathionylation, thus regulating their diverse cytokine-like activities in the context of inflammation (for a comprehensive review, see [29] ).
Conclusions and limits of the present review
The concept of redox regulation is clearly an evolution of the concept of oxidative stress and is obviously more complex. It is not 'black-and-white', but introduces shades of grey. Translating this into the field of innate immunity and inflammation, this complexity probably explains why antioxidants are not good drugs, as they affect a number of regulatory mechanisms. On the other hand, this does by no means imply that GSH depletion is not detrimental. In fact, GSH is doubly important, not only as an antioxidant, but also as a signalling molecule. This probably explains why glutathione (both GSH and GSSG) depletion is often associated with an increased susceptibility to infection (defective immunity) or inflammation (exaggerated immunity) [12] .
Finally, just for the reader to be aware, we should mention that the present mini-review did not discuss S-nitrosylation, which is clearly another form of oxidation of protein thiols of great importance in inflammation and immunity. Also we have not discussed the relevance of protein thiols in HIV. 
